Mariasanta Napolitano

List of Publications by Year
in descending order

87	1,430	393982 19	377514 34
papers	citations	h-index	g-index

87	87	87	1906
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study. Journal of Clinical Oncology, 2014, 32, 3607-3612.	0.8	91
2	Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica, 2013, 98, 538-544.	1.7	82
3	The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfusion, 2015, 13, 559-68.	0.3	78
4	Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation â€“ the surgical STER. British Journal of Haematology, 2011, 152, 340-346.	1.2	75
5	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	1.9	64
6	Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy. Journal of Clinical Medicine, 2017, 6, 38.	1.0	63
7	Acquired haemophilia in cancer: A systematic and critical literature review. Haemophilia, 2018, 24, 43-56.	1.0	57
8	Hereditary combined deficiency of the vitamin K-dependent clotting factors. Orphanet Journal of Rare Diseases, 2010, 5, 21.	1.2	51
9	Replacement therapy for bleeding episodes in factor VII deficiency. Thrombosis and Haemostasis, 2013, 109, 238-247.	1.8	48
10	Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses. Annals of Hematology, 2014, 93, 557-563.	0.8	38
11	Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. Journal of Thrombosis and Haemostasis, 2017, 15, 1757-1763.	1.9	38
12	Women with congenital factor <scp>VII</scp> deficiency: clinical phenotype and treatment options from two international studies. Haemophilia, 2016, 22, 752-759.	1.0	36
13	Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfusion, 2019, 17, 171-180.	0.3	32
14	Immunosenescence and lymphomagenesis. Immunity and Ageing, 2018, 15, 22.	1.8	30
15	Invasive procedures and minor surgery in factor VII deficiency. Haemophilia, 2012, 18, e63-5.	1.0	29
16	Inhibitors to factor <scp>VII</scp> in congenital factor <scp>VII</scp> deficiency. Haemophilia, 2014, 20, e188-91.	1.0	27
17	Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature. Critical Reviews in Oncology/Hematology, 2018, 124, 41-50.	2.0	26
18	Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits. Frontiers in Medicine, 2019, 6, 261.	1.2	25

#	Article	IF	Citations
19	Activated prothrombin complex concentrate (<scp>FEIBA</scp>^{Â®}) in acquired haemophilia A: a large multicentre Italian study â€“ the <scp>FAIR</scp> Registry. British Journal of Haematology, 2019, 184, 853-855.	1.2	24
20	The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep. Plasmatology, 2020, 13, 263485352097821.	4.0	22
21	Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia?. Haemophilia, 2020, 26, 117-121.	1.0	20
22	Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. International Journal of Molecular Sciences, 2021, 22, 561.	1.8	20
23	Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency. Haematologica, 2012, 97, 705-709.	1.7	19
24	Role of clinical and laboratory parameters for treatment choice in patients with inherited <scp>FVII</scp> deficiency undergoing surgical procedures: evidence from the <scp>STER</scp> registry. British Journal of Haematology, 2018, 180, 563-570.	1.2	19
25	Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Preference and Adherence, 2018, Volume 12, 431-441.	0.8	19
26	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	1.9	19
27	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	1.0	18
28	Clinical and biological data on the use of hydroxychloroquine against SARSâ€CoVâ€2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease. Journal of Medical Virology, 2021, 93, 124-126.	2.5	18
29	Correlation between <scp>FIX</scp> genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study. Haemophilia, 2016, 22, 537-542.	1.0	17
30	Replacement therapy in inherited factor VII deficiency: occurrence of adverse events and relation with surgery. Haemophilia, 2015, 21, e513-7.	1.0	16
31	Consensus statements on vaccination in patients with haemophiliaâ€"Results from the Italian haemophilia and vaccinations (HEVA) project. Haemophilia, 2019, 25, 656-667.	1.0	16
32	Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency. Journal of Thrombosis and Haemostasis, 2008, 6, 797-803.	1.9	14
33	Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study. Leukemia and Lymphoma, 2016, 57, 116-119.	0.6	14
34	A multicenter realâ€life study on anticoagulant treatment with direct oral anticoagulants in patients with <scp>P</scp>hâ€negative myeloproliferative neoplasms. American Journal of Hematology, 2020, 95, E329-E332.	2.0	14
35	Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?. Biomedicines, 2021, 9, 1170.	1.4	14
36	Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. Thrombosis and Haemostasis, 2014, 112, 424-425.	1.8	13

#	Article	IF	Citations
37	Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study. Annals of Hematology, 2021, 100, 2173-2179.	0.8	12
38	Ultrasonography-guided central venous catheterisation in haematological patients with severe thrombocytopenia. Blood Transfusion, 2013, 11, 506-9.	0.3	12
39	Lymphomas and thyroid: Bridging the gap. Hematological Oncology, 2018, 36, 519-524.	0.8	11
40	Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry. Thrombosis Research, 2019, 174, 24-26.	0.8	10
41	Unusual onset of venous thromboembolism and heparin-induced thrombocytopenia in a patient with essential thrombocythemia. Blood Coagulation and Fibrinolysis, 2010, 21, 85-90.	0.5	9
42	Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate. Clinical Case Reports (discontinued), 2017, 5, 1573-1575.	0.2	9
43	F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. Journal of Thrombosis and Haemostasis, 2022, 20, 69-81.	1.9	9
44	Cardio-oncology in multiple myeloma: is it time for a specific focus?. Leukemia and Lymphoma, 2018, 59, 1764-1766.	0.6	8
45	Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs. Haematologica, 2019, 104, e470-e473.	1.7	8
46	Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962091829.	0.7	8
47	Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms. Journal of Personalized Medicine, 2022, 12, 364.	1.1	8
48	Subcortical ischaemic changes in young hypertensive patients: frequency, effect on cognitive performance and relationship with markers of endothelial and haemostatic activation. European Journal of Neurology, 2007, 14, 1222-1229.	1.7	7
49	Effective Hemostasis During Minor Surgery in a Case of Hereditary Combined Deficiency of Vitamin K-dependent Clotting Factors. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 221-223.	0.7	7
50	Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres. Seminars in Thrombosis and Hemostasis, 2016, 42, 036-041.	1.5	7
51	Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer. Journal of Thrombosis and Thrombolysis, 2018, 46, 404-408.	1.0	7
52	Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres. British Journal of Haematology, 2022, 196, 871-883.	1.2	7
53	Abdominal aortic thrombosis secondary to reactive thrombocytosis in a patient with iron deficiency anemia. Annals of Hematology, 2016, 95, 1389-1390.	0.8	6
54	Coagulation and Clinical Features Associated with the Arg304gln Mutation (Factor VII Padua) in the Irf7 Study Group Response to Letter to the Editor Regarding â€œFactor VII Deficiency (Semin Thromb) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	6

#	Article	IF	Citations
55	Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory drugs. Leukemia and Lymphoma, 2015, 56, 1507-1509.	0.6	5
56	Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies. Transfusion and Apheresis Science, 2018, 57, 578-581.	0.5	5
57	<p>Emotions and Opinions of Adult Patients with Haemophilia During the COVID-19 (Coronavirus) Tj ETQq1 1 0.784314 rgBT /C Adherence, 2020, Volume 14, 1145-1147.	0.8	5
58	Addressing the impact of SARSâ€CoVâ€2 infection in persons with congenital bleeding disorders: The Italian MECCOVIDâ€19 study. Haemophilia, 2021, 27, e575-e578.	1.0	5
59	Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The â€œCirculating Woundâ€•Model. International Journal of Molecular Sciences, 2021, 22, 11343.	1.8	4
60	Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment. Blood Coagulation and Fibrinolysis, 2008, 19, 453-457.	0.5	3
61	Coronary artery stenosis treatment in aging patients with inherited Factor VII deficiency: Where do we stand?. Transfusion and Apheresis Science, 2017, 56, 867-869.	0.5	3
62	Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs. Hematology Reports, 2018, 10, 7523.	0.3	3
63	Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia. Transfusion and Apheresis Science, 2019, 58, 102666.	0.5	3
64	The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A. Drugs in R and D, 2019, 19, 381-390.	1.1	3
65	Haemorheological profile in congenital afibrinogenemia and in congenital dysfibrinogenemia: A clinical case report. Clinical Hemorheology and Microcirculation, 2020, 73, 523-530.	0.9	3
66	Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series. Transfusion and Apheresis Science, 2020, 59, 102897.	0.5	3
67	ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers. Seminars in Thrombosis and Hemostasis, 2021, 47, 084-089.	1.5	3
68	Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis. Annals of Hematology, 2021, 100, 653-659.	0.8	3
69	Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party. Blood Transfusion, 2016, 14, 521-526.	0.3	3
70	Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report. Transplantation Proceedings, 2012, 44, 2033-2035.	0.3	2
71	Endovascular treatment of chronic cerebro spinal venous insufficiency in patients with multiple sclerosis modifies circulating markers of endothelial dysfunction and coagulation activation. Blood Coagulation and Fibrinolysis, 2014, 25, 716-720.	0.5	2
72	Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report. Annals of Hematology, 2015, 94, 1597-1598.	0.8	2

#	Article	IF	Citations
73	Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with Î²â€thalassemia: results from a preliminary study. Transfusion, 2016, 56, 827-830.	0.8	2
74	Prolonged anticoagulant treatment in patients with cancer: Where do we stand?. Thrombosis Research, 2017, 158, 152-153.	0.8	2
75	Future directions in acquired hemophilia A. Blood, 2021, 137, 294-295.	0.6	2
76	Pharmacokinetics of Factor VII. Blood, 2011, 118, 2259-2259.	0.6	2
77	Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with) Tj ETQq1 1 0.784314 rgBT /Overlock	0.3	2
78	Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma. Haemophilia, 2010, 16, 185-187.	1.0	1
79	Plasma viscosity pattern and erythrocyte aggregation in two patients with congenital afibrinogenemia. Blood Coagulation and Fibrinolysis, 2020, 31, 330-332.	0.5	1
80	Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study . Journal of Blood Medicine, 2020, Volume 11, 251-258.	0.7	1
81	Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40Â°C. Journal of Blood Medicine, 2021, Volume 12, 9-20.	0.7	1
82	A Platelet Defect Modulates Bleeding in Mild Hemophilia: The Tale of 2 Brothers. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 715-716.	0.7	0
83	Reply to E.G. Urrego et al. Journal of Clinical Oncology, 2015, 33, 1713-1714.	0.8	0
84	Peripheral circulating cells with paroxysmal nocturnal haemoglobinuria phenotype after a first episode of cerebral sinus vein thrombosis: Results from a multicentre cross-sectional study. Thrombosis Research, 2020, 185, 85-87.	0.8	0
85	Coexistence of Von Willebrand disease and gastrointestinal stromal tumor (G.I.S.T): Case report of a rare and challenge association. Transfusion and Apheresis Science, 2020, 59, 102805.	0.5	0
86	Functional In Vitro Studies Of Buffy Coat Pooled Platelets Cryopreserved In Dimethyl-Sulphoxide With a New System. Blood, 2013, 122, 1158-1158.	0.6	0
87	Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience.. Blood, 0, , .	0.6	0